pH-Sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer

Bakry Ibrahim; Omar Y Mady; Murtaza M Tambuwala; Yusuf A Haggag

doi:10.2217/nnm-2021-0423

pH-Sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer

Bakry Ibrahim, Omar Y Mady, Murtaza M Tambuwala, Yusuf A Haggag

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

81 Downloads (Pure)

Abstract

Background: Parenteral administration of chemotherapeutic drugs, 5-fluorouracil (5-FU) and leucovorin (LV), is commonly used to treat large bowel carcinomas such as colon cancer (CC) and colorectal carcinoma (CRC).
Aim: Our study aims to design a novel nanoparticulate drug-delivery vehicle for oral use capable of colon-specific release.
Methods: A modified double-emulsion solvent evaporation method was used in the preparation of pH-responsive Eudargit® S100 polymeric nanoparticles, loaded with 5-FU/LV combination (5-FU/LV-loaded Eudargit S100 NPs).
Results: Our optimized drug-loaded NP showed a pH-responsive drug release and exhibited significantly more cytotoxic actions in cancer-cell lines than free drugs.
Conclusion: These findings open the way for conducting clinical trials for colon malignancies treated with nanoparticles.

Original language	English
Pages (from-to)	367-381
Number of pages	15
Journal	NANOMEDICINE
Volume	17
Issue number	6
Early online date	3 Feb 2022
DOIs	https://doi.org/10.2217/nnm-2021-0423
Publication status	Published (in print/issue) - 31 Mar 2022

Bibliographical note

Funding Information:
Financial support for research work was provided by Tanta University, Egypt. Open Access was funded by Ulster University under their Read and Publish agreement with the publisher. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Publisher Copyright:
© 2022 The Authors.

Keywords

5-fluorouracil
Research Article
colon targeting
eudragit S100
large bowel carcinoma
leucovorin
nanoparticles
oral delivery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/nnm-2021-0423Licence: CC BY

nnm-2021-0423Final published version, 9.55 MBLicence: CC BY

Cite this

@article{1cafe01d1ec444f3aee73393fa7c9230,

title = "pH-Sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer",

abstract = "Background: Parenteral administration of chemotherapeutic drugs, 5-fluorouracil (5-FU) and leucovorin (LV), is commonly used to treat large bowel carcinomas such as colon cancer (CC) and colorectal carcinoma (CRC). Aim: Our study aims to design a novel nanoparticulate drug-delivery vehicle for oral use capable of colon-specific release. Methods: A modified double-emulsion solvent evaporation method was used in the preparation of pH-responsive Eudargit{\textregistered} S100 polymeric nanoparticles, loaded with 5-FU/LV combination (5-FU/LV-loaded Eudargit S100 NPs). Results: Our optimized drug-loaded NP showed a pH-responsive drug release and exhibited significantly more cytotoxic actions in cancer-cell lines than free drugs. Conclusion: These findings open the way for conducting clinical trials for colon malignancies treated with nanoparticles.",

keywords = "5-fluorouracil, Research Article, colon targeting, eudragit S100, large bowel carcinoma, leucovorin, nanoparticles, oral delivery",

author = "Bakry Ibrahim and Mady, {Omar Y} and Tambuwala, {Murtaza M} and Haggag, {Yusuf A}",

note = "Funding Information: Financial support for research work was provided by Tanta University, Egypt. Open Access was funded by Ulster University under their Read and Publish agreement with the publisher. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2022 The Authors.",

year = "2022",

month = mar,

day = "31",

doi = "10.2217/nnm-2021-0423",

language = "English",

volume = "17",

pages = "367--381",

journal = "NANOMEDICINE",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - pH-Sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer

AU - Ibrahim, Bakry

AU - Mady, Omar Y

AU - Tambuwala, Murtaza M

AU - Haggag, Yusuf A

N1 - Funding Information: Financial support for research work was provided by Tanta University, Egypt. Open Access was funded by Ulster University under their Read and Publish agreement with the publisher. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2022 The Authors.

PY - 2022/3/31

Y1 - 2022/3/31

N2 - Background: Parenteral administration of chemotherapeutic drugs, 5-fluorouracil (5-FU) and leucovorin (LV), is commonly used to treat large bowel carcinomas such as colon cancer (CC) and colorectal carcinoma (CRC). Aim: Our study aims to design a novel nanoparticulate drug-delivery vehicle for oral use capable of colon-specific release. Methods: A modified double-emulsion solvent evaporation method was used in the preparation of pH-responsive Eudargit® S100 polymeric nanoparticles, loaded with 5-FU/LV combination (5-FU/LV-loaded Eudargit S100 NPs). Results: Our optimized drug-loaded NP showed a pH-responsive drug release and exhibited significantly more cytotoxic actions in cancer-cell lines than free drugs. Conclusion: These findings open the way for conducting clinical trials for colon malignancies treated with nanoparticles.

AB - Background: Parenteral administration of chemotherapeutic drugs, 5-fluorouracil (5-FU) and leucovorin (LV), is commonly used to treat large bowel carcinomas such as colon cancer (CC) and colorectal carcinoma (CRC). Aim: Our study aims to design a novel nanoparticulate drug-delivery vehicle for oral use capable of colon-specific release. Methods: A modified double-emulsion solvent evaporation method was used in the preparation of pH-responsive Eudargit® S100 polymeric nanoparticles, loaded with 5-FU/LV combination (5-FU/LV-loaded Eudargit S100 NPs). Results: Our optimized drug-loaded NP showed a pH-responsive drug release and exhibited significantly more cytotoxic actions in cancer-cell lines than free drugs. Conclusion: These findings open the way for conducting clinical trials for colon malignancies treated with nanoparticles.

KW - 5-fluorouracil

KW - Research Article

KW - colon targeting

KW - eudragit S100

KW - large bowel carcinoma

KW - leucovorin

KW - nanoparticles

KW - oral delivery

UR - http://www.scopus.com/inward/record.url?scp=85125289995&partnerID=8YFLogxK

UR - https://pubmed.ncbi.nlm.nih.gov/35109714/

UR - https://www.futuremedicine.com/doi/10.2217/nnm-2021-0423

U2 - 10.2217/nnm-2021-0423

DO - 10.2217/nnm-2021-0423

M3 - Article

C2 - 35109714

SN - 1743-5889

VL - 17

SP - 367

EP - 381

JO - NANOMEDICINE

JF - NANOMEDICINE

IS - 6

ER -

pH-Sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this